Table 2.
Comparison of lamivudine and tenofovir groups based on creatinine level, number of patients with creatinine level more than 2 mg/dL, and more than 50% increases in creatinine level
| Variables | Lamivudine group | Tenofovir group | P. value |
|---|---|---|---|
| Creatinine level (mean ± SD; mg/dL) | |||
| 1month | 1.39 ± 0.54 | 1.25 ±0 .39 | 0.016 |
| 6 months | 1.27 ± 0.27 | 1.16 ± 0.31 | 0.008 |
| 12 months | 1.19 ± 0 .23 | 1.19 ± 0.21 | 0.97 |
| After 12 months | 1.19 ± 0.20 | 1.19 ± 0.22 | 0.97 |
| Number of patients with Creatinine level more than 2 mg/dL (n, %) | |||
| 1month | 4 (4.3%) | 12 (5.7%) | 0.78 * |
| 6 months | 1 (1.3%) | 1 (0.5%) | 0.47 * |
| 12 months | 0 (0%) | 2 (1%) | 1* |
| After 12 months | 0 (0%) | 2 (1.1%) | 1* |
| Number of patients with more than 50% increases in creatinine level (n, %) | |||
| 6 months | 3 (4.1%) | 6 (3%) | 0.70* |
| 12 months | 1 (1.6%) | 8 (3.2%) | 0.68* |
| After 12 months | 0 (0%) | 8 (4.4%) | 0.2* |
* Fisher’s Exact Test